Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-02-25FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for paroxetine hydrochloride from Zydus Lifesciences Limited, applying to the generic product.
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: Pilot Study of Annie Text Messaging for Depression Treatment Adherence [NA]
A completed pilot clinical trial evaluating Annie text messaging to improve treatment adherence for depression; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-02-15Clinical Trial Update: Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators [NA]
A completed clinical trial evaluated whether treating caregiver depression improves childhood asthma outcomes and explored mediators of any …
-
CLINICAL_TRIALS trial_result · 2022-02-14Clinical Trial Update: Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression [Phase 4]
Phase 4 trial comparing vortioxetine and desvenlafaxine in adults with Major Depressive Disorder has completed.
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: COVID-19 and the Healthy Minds Program for Educators [NA]
A completed clinical trial evaluating the Healthy Minds Program for Educators in the context of COVID-19, addressing anxiety and depression,…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-02-09FDA Approved: DOXEPIN HYDROCHLORIDE — Original Application (First Nation Group, LLC)
FDA approved the original application for a generic doxepin hydrochloride product from First Nation Group, LLC, enabling its marketing in th…
-
CLINICAL_TRIALS trial_result · 2022-02-07Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy [Phase 2]
A Phase 2 study evaluating JNJ-42847922 as an adjunct to antidepressants in adults with major depressive disorder who had an inadequate resp…
-
FDA approval · 2022-02-04FDA Approved: CELEXA — Supplemental Application (Allergan, Inc.)
The FDA approves a supplemental application for CELEXA (citalopram) from Allergan, Inc., updating or expanding the product's labeling.
-
FDA approval · 2022-02-02FDA Approved: BUPROPION HYDROCHLORIDE — Original Application (Granules Pharmaceuticals Inc.)
FDA approved Bupropion hydrochloride as an original-application generic product by Granules Pharmaceuticals Inc.; the product is indicated f…
-
FDA approval · 2022-01-31FDA Approved: CITALOPRAM — Original Application (Almatica Pharma LLC)
FDA approves Citalopram under an Original Application filed by Almatica Pharma LLC. The approval adds Citalopram as a treatment option for m…
-
CLINICAL_TRIALS trial_result · 2022-01-26Clinical Trial Update: Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK) [Phase 2]
Phase 2 trial investigating pathophysiology of neurodegeneration in late-life depression using AV45+THK.
-
FDA approval · 2022-01-25FDA Approved: DULOXETINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for a generic duloxetine hydrochloride product from Aurobindo Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2022-01-20Clinical Trial Update: THINC-it Vortioxetine - Sensitivity to Change [Phase 2, Phase 3]
This entry reports results from Phase 2 and Phase 3 trials of vortioxetine evaluating sensitivity to cognitive change in adults with Major D…
-
FDA approval · 2022-01-19FDA Approved: PAROXETINE — Supplemental Application (NorthStar Rx LLC)
The FDA granted a supplemental approval for paroxetine hydrochloride (paroxetine) from NorthStar Rx LLC under an ANDA. This approval confirm…
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: rTMS for Depressed Teens: A Sham-Controlled Trial, Part 2 [NA]
A sham-controlled trial update on repetitive transcranial magnetic stimulation (rTMS) for adolescents with major depressive disorder; the st…
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: rTMS for Depressed Teens: A Sham-Controlled Trial, Part 1 [NA]
A sham-controlled trial of repetitive transcranial magnetic stimulation (rTMS) for adolescents with major depressive disorder was terminated…
-
CLINICAL_TRIALS trial_result · 2022-01-10Clinical Trial Update: Adjunctive D-Cycloserine in Major Depressive Disorder [Phase 2]
A Phase 2 trial evaluating adjunctive D-Cycloserine for major depressive disorder has completed.
-
FDA approval · 2022-01-05FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for bupropion hydrochloride from Sun Pharmaceutical Industries, authorizing the generic product’s ma…
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Modulating Default Mode Network Function: A Transcranial Direct Current Stimulation (TDCS) Pilot Study [NA]
Pilot study evaluating transcranial direct current stimulation (TDCS) to modulate default mode network function in depression and anxiety; s…
-
FDA approval · 2022-01-03FDA Approved: BUPROPION HYDROCHLORIDE XL — Supplemental Application (Slate Run Pharmaceuticals, LLC)
The FDA approved a supplemental application for Bupropion Hydrochloride XL from Slate Run Pharmaceuticals, LLC.
-
FDA approval · 2022-01-03FDA Approved: SPRAVATO — Supplemental Application (Janssen Pharmaceuticals Inc.)
FDA approves Janssen's supplemental application for SPRAVATO (esketamine) to update its labeling for use in depression.
-
CLINICAL_TRIALS trial_result · 2021-12-22Clinical Trial Update: To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) [Phase 3]
A Phase 3 trial assessing safety and tolerability of an oral aripiprazole/escitalopram combination in adults with major depressive disorder …
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) [Phase 3]
Phase 3 study evaluating an oral aripiprazole/escitalopram combination for major depressive disorder was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-12-15Clinical Trial Update: Effects of Psilocybin in Major Depressive Disorder [Phase 2]
Phase 2 trial results for psilocybin in major depressive disorder have been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-12-13Clinical Trial Update: A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19 [NA]
A completed clinical trial evaluating a CBT-based mobile intervention as first-line treatment for adolescent depression during COVID-19; res…